Metformin as a multi-target modulator of atherosclerosis: integrated regulation of Nrf2/KLF2, mitochondrial homeostasis, inflammation, ferroptosis, and innate immunity
Journal of Pharmacy and Pharmacology · 2026
DOI: 10.1093/jpp/rgag056 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmacy and Pharmacology, 2026. Verfasst von Mansour Alanazi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, College of Medicine, Northern Border University, Arar 73213, Saudi Arabia. Hauptthemen laut MEDLINE: Kruppel-Like Transcription Factors, Atherosclerosis, Metformin, NF-E2-Related Factor 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 147 Literaturangaben.
Abstract (Originalsprache)
Objectives
Atherosclerosis (AS) is a chronic inflammatory vascular disorder driven by endothelial dysfunction, oxidative stress, lipid dysregulation, mitochondrial injury, and maladaptive immune activation. Metformin, the first-line therapy for type 2 diabetes, has vasculoprotective effects beyond glycemic control. This review summarizes current evidence on metformin as a multi-target modulator of AS through regulation of nuclear erythroid 2-related factor 2 (Nrf2)/Krüppel-like factor 2 (KLF2) signaling, AMP-activated protein kinase (AMPK)/sirtuin-1 pathways, cyclic GMP-AMP synthase and stimulator of interferon genes (cGAS–STING) signaling, mitochondrial homeostasis, lipid metabolism, and inflammation.
Methods
Relevant studies were identified through PubMed, Web of Science, Google Scholar, and China National Knowledge Infrastructure databases, focusing on the effects of metformin on atherosclerosis and related pathways involving oxidative stress, mitochondrial function, ferroptosis, inflammation, and innate immunity. Key findings Metformin enhances antioxidant defenses by activating Nrf2 through Kelch-like ECH-associated protein 1 degradation and increasing cytoprotective mediators such as heme oxygenase-1 and NAD(P)H quinone oxidoreductase 1. It also modulates cGAS–STING signaling and promotes AMPK-mediated KLF2 activation, thereby improving endothelial quiescence, increasing endothelial nitric oxide synthase–derived nitric oxide, and suppressing inflammatory signaling and adhesion molecules. Furthermore, metformin protects against ferroptosis by stabilizing mitochondrial function, reducing lipid peroxidation, and limiting iron-dependent oxidative injury. It also exerts systemic anti-atherogenic effects by modulating gut microbiota, lowering trimethylamine-N-oxide, and increasing short-chain fatty acids and glucagon-like peptide-1.
Conclusions
Metformin attenuates plaque formation, inflammation, expansion of the necrotic core, and instability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, College of Medicine, Northern Border University, Arar 73213, Saudi Arabia.
- Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad 14022, Iraq.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Egyptian Russian University, Badr City 11829, Cairo, Egypt.
- Department of Internal Medicine, College of Medicine, Jouf University, Sakaka 72388, Saudi Arabia.
- European Academy of Sciences and Arts, Salzburg, Austria.
- University Centre for Research & Development, Chandigarh University, Chandigarh-Ludhiana Highway, Mohali, Punjab 140413, India.
ORCID-Profile: Aya M Mustafa, Marios Papadakis
Zitieren
APA
Alanazi, M., Al-Kuraishy, H. M., Mustafa, A. M., Alruwaili, M., Alexiou, A., Papadakis, M., & Batiha, G. E. (2026). Metformin as a multi-target modulator of atherosclerosis: integrated regulation of Nrf2/KLF2, mitochondrial homeostasis, inflammation, ferroptosis, and innate immunity. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgag056
Vancouver
Alanazi M, Al-Kuraishy HM, Mustafa AM, Alruwaili M, Alexiou A, Papadakis M, et al. Metformin as a multi-target modulator of atherosclerosis: integrated regulation of Nrf2/KLF2, mitochondrial homeostasis, inflammation, ferroptosis, and innate immunity. Journal of Pharmacy and Pharmacology. 2026. doi:10.1093/jpp/rgag056
BibTeX
@article{Alanazi2026,
author = {Alanazi, Mansour and Al-Kuraishy, Hayder M and Mustafa, Aya M and Alruwaili, Mubarak and Alexiou, Athanasios and Papadakis, Marios and Batiha, Gaber El-Saber},
title = {Metformin as a multi-target modulator of atherosclerosis: integrated regulation of Nrf2/KLF2, mitochondrial homeostasis, inflammation, ferroptosis, and innate immunity},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
doi = {10.1093/jpp/rgag056}
}
EUVIMED